BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 14607753)

  • 21. Assessment of clonal stability of minimal residual disease targets between 1st and 2nd relapse of childhood precursor B-cell acute lymphoblastic leukemia.
    Guggemos A; Eckert C; Szczepanski T; Hanel C; Taube T; van der Velden VH; Graf-Einsiedel H; Henze G; Seeger K
    Haematologica; 2003 Jul; 88(7):737-46. PubMed ID: 12857551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection.
    Burnusuzov HA; Spasova MI; Murdjeva MA; Stoyanova AA; Mumdziev IN; Kaleva VI; Belcheva MI; Bosheva MN
    Folia Med (Plovdiv); 2016 Mar; 58(1):28-35. PubMed ID: 27383875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
    Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
    Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry.
    Mejstríková E; Fronková E; Kalina T; Omelka M; Batinić D; Dubravcić K; Pospísilová K; Vásková M; Luria D; Cheng SH; Ng M; Leung Y; Kappelmayer J; Kiss F; Izraeli S; Stark B; Schrappe M; Trka J; Starý J; Hrusák O
    Pediatr Blood Cancer; 2010 Jan; 54(1):62-70. PubMed ID: 19760767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.
    Björklund E; Mazur J; Söderhäll S; Porwit-MacDonald A
    Leukemia; 2003 Jan; 17(1):138-48. PubMed ID: 12529671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection.
    Gaipa G; Basso G; Maglia O; Leoni V; Faini A; Cazzaniga G; Bugarin C; Veltroni M; Michelotto B; Ratei R; Coliva T; Valsecchi MG; Biondi A; Dworzak MN;
    Leukemia; 2005 Jan; 19(1):49-56. PubMed ID: 15538405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
    Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
    Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological and clinical features of B-precursor childhood acute lymphoblastic leukemia showing CD2 and/or E-rosette co-expression.
    Cantù-Rajnoldi A; Putti MC; Schirò R; Biondi A; Cattoretti G; Valeggio C; Castagni M; Basso G
    Haematologica; 1992; 77(5):384-91. PubMed ID: 1362385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.
    Malec M; van der Velden VH; Björklund E; Wijkhuijs JM; Söderhäll S; Mazur J; Björkholm M; Porwit-MacDonald A
    Leukemia; 2004 Oct; 18(10):1630-6. PubMed ID: 15295608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cells antigens' expression modulation during induction treatment of childhood acute lymphoblastic leukemia].
    Pawińska-Wasikowska K; Balwierz W
    Przegl Lek; 2010; 67(6):361-5. PubMed ID: 21344762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Application of triple-color flow cytometry for minimal residual disease detection in acute B-lymphoblastic leukemia].
    Chen T; Zhu Y; Zhou X; Wang Y; Ying D
    Zhonghua Xue Ye Xue Za Zhi; 2001 Jan; 22(1):20-3. PubMed ID: 11877045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
    J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells.
    Gaipa G; Basso G; Aliprandi S; Migliavacca M; Vallinoto C; Maglia O; Faini A; Veltroni M; Husak D; Schumich A; Ratei R; Biondi A; Dworzak MN;
    Cytometry B Clin Cytom; 2008 May; 74(3):150-5. PubMed ID: 18271020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies.
    Moos M; Schulz R; Cremer F; Sucker C; Schmohl D; Döhner H; Goldschmidt H; Haas R; Hunstein W
    Stem Cells; 1995 Dec; 13 Suppl 3():42-51. PubMed ID: 8747988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoglobulin light chain gene rearrangements in precursor-B-acute lymphoblastic leukemia: characteristics and applicability for the detection of minimal residual disease.
    van der Velden VH; de Bie M; van Wering ER; van Dongen JJ
    Haematologica; 2006 May; 91(5):679-82. PubMed ID: 16627258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia.
    Zetterquist H; Mattsson J; Uzunel M; Näsman-Björk I; Svenberg P; Tammik L; Bayat G; Winiarski J; Ringdén O
    Bone Marrow Transplant; 2000 Apr; 25(8):843-51. PubMed ID: 10808205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction.
    Ratei R; Basso G; Dworzak M; Gaipa G; Veltroni M; Rhein P; Biondi A; Schrappe M; Ludwig WD; Karawajew L;
    Leukemia; 2009 Mar; 23(3):528-34. PubMed ID: 19020543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement.
    Morishima Y; Miyamura K; Kojima S; Ueda R; Morishita Y; Sao H; Tanimoto M; Ohno R; Sobue R; Hirano M
    Bone Marrow Transplant; 1993 Apr; 11(4):255-9. PubMed ID: 7683550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative phenotype mapping of normal vs. malignant pediatric B-lymphopoiesis unveils leukemia-associated aberrations.
    Dworzak MN; Fritsch G; Fleischer C; Printz D; Fröschl G; Buchinger P; Mann G; Gadner H
    Exp Hematol; 1998 Apr; 26(4):305-13. PubMed ID: 9546313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
    Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T
    Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.